HER3 Alterations in Cancer and Potential Clinical Implications

In recent years, the third member of the HER family, kinase impaired HER3, has become a target of interest in cancer as there is accumulating evidence that HER3 plays a role in tumor growth and progression. This review focuses on HER3 activation in bladder, breast, colorectal, and lung cancer diseas...

Full description

Saved in:
Bibliographic Details
Published in:Cancers 2022-12, Vol.14 (24), p.6174
Main Authors: Kilroy, Mary Kate, Park, SoYoung, Feroz, Wasim, Patel, Hima, Mishra, Rosalin, Alanazi, Samar, Garrett, Joan T
Format: Article
Language:English
Subjects:
Bladder cancer
Breast cancer
Cancer
Cancer therapies
Cell growth
Chemotherapy
Colon
Development and progression
Drug delivery
Drug targeting
Epidermal growth factor
Gene mutations
Genetic aspects
Health aspects
Hematuria
Kinases
Ligands
Lung cancer
Lung diseases
Medical prognosis
Metastasis
Mutation
Patients
Pharmaceutical research
Phosphorylation
Physiological aspects
Protein tyrosine kinase
Proteins
Review
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In recent years, the third member of the HER family, kinase impaired HER3, has become a target of interest in cancer as there is accumulating evidence that HER3 plays a role in tumor growth and progression. This review focuses on HER3 activation in bladder, breast, colorectal, and lung cancer disease progression. HER3 mutations occur at a rate up to ~10% of tumors dependent on the tumor type. With patient tumors routinely sequenced for gene alterations in recent years, we have focused on HER3 mutations in bladder, breast, colon, and lung cancers particularly in response to targeted therapies and the potential to become a resistance mechanism. There are currently several HER3 targeting drugs in the pipeline, possibly improving outcomes for cancer patients with tumors containing HER3 activation and/or alterations.
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers14246174